WOCKPHARMA Wockhardt Ltd Product Launches Announcement 2025 - New Antibiotic Success Wockhardt's novel antibiotic Zaynich (Zidebactam/Cefepime), in a Phase III study, achieved a 96.8% clinical cure rate for complicated urinary infections, attracting global interest for compassionate use..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Wockhardt Ltd